Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina

Additional Phase 2 data read-outs expected in 4Q 2023, including topline from the IMPROVE-HCM in non-obstructive hypertrophic cardiomyopathy and interim data from IMPROVE-DiCE in cardiometabolic heart failure with preserved ejection fraction (HFpEF) 

Related Keywords

Finland ,Juhani Knuuti ,Coll Cardiol ,Centre In Turku ,Imbria Pharmaceuticals Inc ,Imbria Pharmaceuticals ,Jai Patel ,Unstable Angina ,